Dataset Information

PDLIM5 gene polymorphisms and short term antidepressant response in Chinese major depressive disorders.

ABSTRACT: Several investigations have suggested that PDLIM5 plays a key role in the pathophysiology of major depressive disorder (MDD), and that PDLIM5 might be a therapeutic target for the action of antidepressant. In this study, we sought to investigate whether variations of PDLIM5 gene sequence could predict response to antidepressants in MDD patients. We selected 3 SNPs (rs10008257, rs2433320, 2452600) of PDLIM5 gene, and performed an association analysis of PDLIM5 and the efficacy of fluoxetine treatment in 185 Han Chinese MDD patients. The results show that the rs2433320 of PDLIM5 gene are associated with fluoxetine therapeutic response in MDD patients (X(2) = 8.2960, df = 2, P = 0.0145) after correction with the Bonferroni multiple test, the HAMD score of the GG genotype group was significantly lower than that of the AA and AG genotype group at 1, 2, 4 and 6 weeks. The results support the idea that the PDLIM5 gene is likely to be involved in the antidepressant response in MDD.

SUBMITTER: Liu Z

PROVIDER: S-EPMC3762623 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

PDLIM5 gene polymorphisms and short term antidepressant response in Chinese major depressive disorders.

Liu Zhongchun Z Zhu Fan F Yao Lihua L Yang Can C Xiao Ling L Zhu Junhong J Wang Huiling H Wang Gaohua G Liu Wanhong W Xiao Zheman Z

International journal of clinical and experimental medicine 20130901 8

Several investigations have suggested that PDLIM5 plays a key role in the pathophysiology of major depressive disorder (MDD), and that PDLIM5 might be a therapeutic target for the action of antidepressant. In this study, we sought to investigate whether variations of PDLIM5 gene sequence could predict response to antidepressants in MDD patients. We selected 3 SNPs (rs10008257, rs2433320, 2452600) of PDLIM5 gene, and performed an association analysis of PDLIM5 and the efficacy of fluoxetine treat ...[more]

PMID: 24040476

Similar Datasets

Project description:BACKGROUND: Increased cortisol levels and genetic polymorphisms have been related to both major depressive disorder and antidepressant treatment outcome. The aim of this study is to evaluate the relationship between circadian salivary cortisol levels, cortisol suppression by dexamethasone and genetic polymorphisms in some HPA axis-related genes to the response to placebo and fluoxetine in depressed patients. METHODS: The diagnosis and severity of depression were performed using the Mini International Neuropsychiatric Interview (M.I.N.I.) and Hamilton depression scale (HAM-D17), respectively. Euthyroid patients were treated with placebo (one week) followed by fluoxetine (20 mg) (two months). Severity of depression was re-evaluated after placebo, three weeks and two months of fluoxetine treatments. Placebo response was defined as HAM-D17 score reductions of at least 25% and to?<?15. Early response and response were reductions of at least 50% after three weeks and two months, and remission with???7 after two months. Plasma TSH, free-T4, circadian salivary cortisol levels and cortisol suppression by dexamethasone were evaluated. Seven genetic polymorphisms located in the Corticotrophin-releasing-hormone-receptor-1 (rs242939, rs242941, rs1876828), Corticotrophin-releasing-hormone-receptor-2 (rs2270007), Glucocorticoid-receptor (rs41423247), FK506-binding-protein-5 (rs1360780), and Arginine-vasopressin (rs3729965) genes were determined. Association analyses between response to placebo/fluoxetine and polymorphism were performed by chi-square or Fisher exact test. Cortisol levels were compared by t-test, ANOVA and the general linear model for repeated measures. RESULTS: 208 depressed patients were recruited, 187 of whom were euthyroid. Placebo responders, fluoxetine responders and remitters exhibited significantly lower circadian cortisol levels than those who did not respond (p-values of 0.014, 0.008 and 0.021 respectively). Patients who abandoned treatment before the third week also exhibited a trend to low cortisol levels (p?=?0.057). The polymorphisms rs242939 (CRHR1) and rs2270007 (CRHR2) were not in Hardy-Weinberg equilibrium. Only the rs242939 polymorphism (CRHR1) exhibited association with early response (three weeks) to fluoxetine (p-value?=?0.043). No other association between outcomes and polymorphisms was observed. CONCLUSIONS: These results support the clinical relevance of low salivary cortisol levels as a predictor of antidepressant response, either to placebo or to fluoxetine. Only one polymorphism in the CRHR1 gene was associated with the early response. Other factors may be involved in antidepressant response, although further studies are needed to identify them.

Dataset Information

PDLIM5 gene polymorphisms and short term antidepressant response in Chinese major depressive disorders.

Publications

PDLIM5 gene polymorphisms and short term antidepressant response in Chinese major depressive disorders.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure